No Picture
News

Tony O’Neill Joins Ajinomoto Bio-Pharma Services’ Leadership Team as Vice President of Compliance

SAN DIEGO: SAN DIEGO, Jan. 25, 2022 /PRNewswire/ — Ajinomoto Bio-Pharma Services ("Aji Bio-Pharma"), a leading global provider of bio-pharmaceutical contract development and manufacturing services, is pleased to announce that Tony O’Neill has joined Aji Bio-Pharma as Vice President of Compliance, US Operations. Mr. O’Neill brings extensive experience leading Quality,… Click here to view original post… […]

No Picture
News

Arcturus Therapeutics Reports New Data Demonstrating Neutralizing Antibody Immune Response to the SARS-CoV-2 Omicron Variant from ARCT-154 and ARCT-165 Booster Clinical Trial

SAN DIEGO–(BUSINESS WIRE)—- $ARCT #ClinicalTrial–Arcturus Reports Data Demonstrating Neutralizing Antibody Immune Response to the SARS-CoV-2 Omicron Variant from ARCT-154 and ARCT-165 Booster Trial Click here to view original post… […]

No Picture
News

Senhwa’s Pidnarulex Receives US FDA Fast Track Designation for the Treatment of Solid Tumors with BRCA1/2, PALB2 and other HR Gene Mutations

TAIPEI and SAN DIEGO: TAIPEI and SAN DIEGO, Jan. 25, 2022 /PRNewswire/ — Senhwa Biosciences, Inc. (TPEx: 6492), a drug development company focusing on first-in-class therapeutics for oncology, rare diseases, and novel coronaviruses, announced today that the US Food and Drug Administration (FDA) has granted Fast Track Designation (FTD) for… Click here to view original post… […]

No Picture
News

Roswell Biotechnologies Demonstrates First Scalable Molecular Electronics Chip in Peer-Review Paper

SAN DIEGO: SAN DIEGO, Jan. 24, 2022 /PRNewswire/ — The first molecular electronics chip has been developed, realizing a 50-year-old goal of integrating single molecules into circuits to achieve the ultimate scaling limits of Moore’s Law. Developed by Roswell Biotechnologies and a multi-disciplinary team of leading academic scientists, the chip… Click here to view original post… […]

No Picture
News

With a $50 Million Gift, USC and UC San Diego Join Forces in Alzheimer’s Research

A joint gift to the University of Southern California (USC) and the University of California San Diego totaling $50 million from the Epstein Family Foundation will drive Alzheimer’s research and accelerate the search for treatments and a cure. Click here to view original post… […]

No Picture
News

DCN Dx Announces Hiring of Mitzi Rettinger as Chief Revenue Officer

CARLSBAD, Calif.: CARLSBAD, Calif., Jan. 24, 2022 /PRNewswire/ — DCN Dx announced today that Mitzi Rettinger has been hired as chief revenue officer reporting directly to Chief Executive Officer Charlie Mamrak. "Mitzi brings decades of sales and marketing experience to the chief revenue officer role," Mamrak said. "She is a… Click here to view original post… […]

No Picture
News

Viking Therapeutics Announces Clinical Hold on Phase 1b Trial of VK0214 in Patients with X-ALD

SAN DIEGO: SAN DIEGO, Jan. 24, 2022 /PRNewswire/ — Viking Therapeutics, Inc. (Viking) (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that its Phase 1b clinical trial of VK0214 in patients with X-linked adrenoleukodystrophy (X-ALD) has been placed… Click here to view original post… […]

No Picture
News

Arcturus Therapeutics Updates Data from ARCT-154 and ARCT-165 Booster Clinical Trial Demonstrating Robust Neutralizing Antibody Responses to SARS-CoV-2 and Several Variants

SAN DIEGO–(BUSINESS WIRE)—- $ARCT #ClinicalTrial–Arcturus Updates Data from ARCT-154 and ARCT-165 Booster Clinical Trial Demonstrating Robust Neutralizing Antibody Responses to SARS-CoV-2 Click here to view original post… […]

No Picture
News

Ionis announces eplontersen receives orphan drug designation from U.S. FDA

CARLSBAD, Calif.: CARLSBAD, Calif., Jan. 24, 2022 /PRNewswire/ — Ionis Pharmaceuticals, Inc. (Nasdaq: IONS), the leader in antisense therapeutics, announced today that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to eplontersen, an investigational antisense medicine for the treatment of people living with transthyretin-mediated amyloidosis, a… Click here to view original post… […]

No Picture
News

Salk appoints Julie A. Auger executive director of Research Operations

LA JOLLA—The Salk Institute announced today the appointment of Julie A. Auger to the position of executive director of Research Operations. Auger will oversee all shared scientific resources at the Institute in her new role, including the scientific technology cores, animal research and shared scientific resources. The position reports… Click here to view original post… […]

No Picture
News

Mirati Therapeutics Presents Positive Clinical Data with Investigational Adagrasib in Patients with KRASG12C-Mutated Gastrointestinal Cancers

SAN DIEGO: SAN DIEGO, Jan. 21, 2022 /PRNewswire/ — Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today announced positive results from a Phase 2 cohort of the KRYSTAL-1 study evaluating adagrasib at the 600mg BID dose in patients with pretreated pancreatic ductal adenocarcinoma and other gastrointestinal (GI)… Click here to view original post… […]

No Picture
News

As Hal Barron steals the show, there’s no off position on the John Maraganore switch; Danny Bar-Zohar makes another leap forward at Merck KGaA

John Maraganore ? The needle on the Maraganore Meter is moving again, as John Maraganore keeps collecting more post-Alnylam roles. First, he and BeiGene co-founder Peter Ho will be strategic advisors for Hillhouse-backed China startup Overland Pharmaceuticals, founded by Hua Mu and Ed Zhang. (By the… Click here to view original post… […]

No Picture
News

Regulus Therapeutics Announces Successful Completion of Pre-IND Meeting with FDA for RGLS8429

SAN DIEGO: SAN DIEGO, Jan. 20, 2022 /PRNewswire/ — Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today announced that the Company has completed a pre-investigational new drug (Pre-IND) meeting with the U.S. Food and… Click here to view original post… […]

No Picture
News

A high-res microscope the size of a toaster? A microscopy startup earns big-name VC backers

When Bo Jing enrolled at Oxford University to be close to his girlfriend, he didn’t expect to invent something that would have investors eagerly digging into their wallets. He was just happy making the best microscope he could. He developed the technology while finishing up his PhD at Oxford, and… Click here to view original post… […]

No Picture
News

OXEIA BIOPHARMACEUTICALS ANNOUNCES NEW BOARD AND MANAGEMENT TEAM MEMBERS AND RELOCATES CORPORATE HEADQUARTERS TO BOSTON

BOSTON: BOSTON, Jan. 20, 2022 /PRNewswire/ — Oxeia Biopharmaceuticals, a clinical stage biotech company conducting Phase 2 clinical trials of OXE103 for treating concussion, today announced two new board members and additions to its executive leadership team. The company also announced its corporate headquarters’ move from San Diego to Boston…. Click here to view original post… […]

No Picture
News

Bluestar Genomics Presents Positive Results of its Pancreatic Cancer Test Performance Evaluation at 2022 ASCO GI Cancers Symposium

SAN DIEGO–(BUSINESS WIRE)–Bluestar Genomics, Inc., an early cancer detection company leading the development and commercialization of next-generation liquid biopsy approaches initially focused on non-invasive detection of high-mortality cancers, today announced positive performance evaluation study results for its pancreatic cancer test. These data confirm that its pancreatic cancer test detects the… Click here to view original post… […]

No Picture
News

Senhwa’s Silmitasertib Receives US FDA Orphan Drug Designation for the Treatment of Biliary Tract Cancer

TAIPEI and SAN DIEGO: TAIPEI and SAN DIEGO, Jan. 20, 2022 /PRNewswire/ — Senhwa Biosciences, Inc. (TPEx: 6492), a drug development company focusing on first-in-class therapeutics for oncology, rare diseases, and novel coronaviruses, announced that the US Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) for Silmitasertib,… Click here to view original post… […]

No Picture
News

BioTheryX Announces Appointment of Sahm Nasseri as Chief Business Officer

SAN DIEGO: SAN DIEGO, Jan. 20, 2022 /PRNewswire/ — BioTheryX, Inc., a clinical-stage company focused on targeted protein degradation to create life-saving medicines, today announced the appointment of Sahm Nasseri as Chief Business Officer. "Sahm is an accomplished biopharma leader with impressive experience in business development, corporate strategy, commercialization and… Click here to view original post… […]

No Picture
News

New Sensor Grids Record Human Brain Signals in Record-Breaking Resolution

A new array of sensors can record electrical signals directly from the surface of the human brain in record-breaking detail: 100 times higher resolution than today’s clinical tools. This could improve neurosurgeons’ ability to remove brain tumors safely and surgically treat drug-resistant epilepsy. Click here to view original post… […]